VLA1601

BIOLOGICAL2 trials

Sponsors

Valneva Austria GmbH

Conditions

ZikaZika VirusZika Virus Infection

Phase 1

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

CompletedNCT03425149

Valneva Austria GmbHZika Virus, Zika Virus Infection

Start: 2018-02-24End: 2018-11-16Updated: 2019-07-05

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

CompletedNCT06334393

Valneva Austria GmbHZika, Zika Virus Infection

Start: 2024-03-25End: 2026-02-27Updated: 2026-03-09